INTERACTIONS OF FLUOXETINE WITH METABOLISM OF DOPAMINE AND SEROTONIN IN RAT-BRAIN REGIONS

被引:55
作者
BALDESSARINI, RJ
MARSH, ER
KULA, NS
机构
[1] HARVARD UNIV,SCH MED,DEPT PSYCHIAT,BELMONT,MA 02178
[2] HARVARD UNIV,SCH MED,NEUROSCI PROGRAM,BELMONT,MA 02178
关键词
EXTRAPYRAMIDAL DISORDER; DOPAMINE; FLUOXETINE; SEROTONIN;
D O I
10.1016/0006-8993(92)90754-W
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Given evidence of inhibitory effects of serotonin on dopaminergic neurotransmission. a series of experiments sought neurochemical evidence of interactions between the selective serotonin transport inhibitor fluoxetine and the metabolism of dopamine (DA) or serotonin (5-HT) in regions of rat brain that might account for extrapyramidal side-effects associated with clinical use of fluoxetine. There were significant inhibitory effects of acute or repeated fluoxetine treatment on the turnover of 5-HT (accumulation of 5-hydroxytryptophan, or ratio of [5-hydroxyindoleacetic acid]/[5-HT]) in striatum, nucleus accumbens and frontal cerebral cortex, but only minor effects on metabolism of DA (accumulation of dihydroxyphenylalanine, or [homovanillic acid]/[DA] ratio), even at high doses or with repeated treatment, and no significant inhibition of the DA metabolism-increasing actions of haloperidol.
引用
收藏
页码:152 / 156
页数:5
相关论文
共 51 条
[1]   ELECTRO-PHYSIOLOGICAL EVIDENCE OF CONCURRENT DORSAL RAPHE INPUT TO CAUDATE, SEPTUM, HABENULA, THALAMUS HIPPOCAMPUS, CEREBELLUM AND OLFACTORY-BULB [J].
ANDERSEN, E ;
RIGOR, B ;
DAFNY, N .
INTERNATIONAL JOURNAL OF NEUROSCIENCE, 1983, 18 (1-2) :107-115
[2]  
BALDESSARINI RJ, 1990, ARCH GEN PSYCHIAT, V47, P191
[3]   EFFECTS OF ISOMERS OF HYDROXYAPORPHINES ON DOPAMINE METABOLISM IN RAT-BRAIN REGIONS [J].
BALDESSARINI, RJ ;
MARSH, ER ;
KULA, NS ;
ZONG, RS ;
GAO, YG ;
NEUMEYER, JL .
BIOCHEMICAL PHARMACOLOGY, 1990, 40 (03) :417-423
[4]   5-HYDROXYTRYPTAMINE AND 5-HYDROXYTRYPTAMINERGIC-DOPAMINERGIC INTERACTIONS IN THE VENTRAL TEGMENTAL AREA OF RAT-BRAIN [J].
BEART, PM ;
MCDONALD, D .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1982, 34 (09) :591-593
[5]  
BELNLOUCIF S, 1991, SOC NEUR ABSTR, V17, P988
[6]  
BERSANI G, 1986, CURR THER RES, V40, P205
[7]  
BOUCHARD RH, 1989, AM J PSYCHIAT, V146, P1352
[8]  
BROD TM, 1989, AM J PSYCHIAT, V146, P1353, DOI 10.1176/ajp.146.10.1353
[9]  
CARBONI E, 1989, EUR J PHARMACOL, V164, P151
[10]  
CHASE TN, 1972, NEUROLOGY, V22, P479, DOI 10.1212/WNL.22.5.479